HLB KRX:028300KOSDAQ

HLB · Korean news coverage and regulatory filings, organized.

Articles, 24h3
Articles, 7 days25
DART filings, 7 days0
Articles tracked399since Sep 11

In Q2 2026, HLB reported revenue of ₩28.0bn, up 78.0% year on year, and an operating loss of ₩22.5bn. HLB (HLB) appeared in 25 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 27 with 17 articles. The most common catalyst was clinical & approvals (4). It was most often mentioned alongside 글로벌테크놀로지.

Filing signals Revenue +30% 4 quarters of losses Screener

HLB quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩28.0bn+78.0%−₩22.5bn
margin −80.4%
−₩80.4bn
Q1 2026₩18.7bn+5.8%−₩23.2bn
margin −124.1%
−₩40.9bn
Q4 2025 derived₩28.7bn+13.6%−₩29.4bn
margin −102.5%
−₩29.3bn
Q3 2025₩22.1bn+30.4%−₩23.0bn
margin −104.1%
−₩76.4bn
Q2 2025₩15.7bn+6.3%−₩23.1bn
margin −146.6%
−₩60.8bn
Q1 2025₩17.7bn+58.4%−₩28.8bn
margin −162.8%
−₩68.9bn
Q4 2024 derived₩25.2bn+179.6%−₩25.7bn
margin −101.9%
−₩29.7bn
Q3 2024₩17.0bn+74.2%−₩19.6bn
margin −115.4%
₩590m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

HLB top stories 2 weeks, by number of outlets

  1. 1
    HLB "진양곤 의장, 계열사 주식 8만주 추가 매수"
    7 outlets · 8 articlesFirst report Oct 21 10:12 뉴시스경제
  2. 2
  3. 3
    HLB 엘레바, ESMO서 '리픽투' 임상 성과 공유…미국 출시 준비 속도
    2 outlets · 2 articlesFirst report Oct 27 10:21 메디컬투데이
  4. 4
    HLB 엘레바, ESMO서 항암 파이프라인 임상 성과 발표
    2 outlets · 2 articlesFirst report Oct 27 09:48 뉴스핌
  5. 5
    HLB 엘레바, ESMO 2026서 글로벌 의료진과 교류…항암제 임상 결과 발표
    1 outlets · 1 articlesFirst report Oct 27 14:37 한국면세뉴스Clinical trial글로벌테크놀로지
  6. 6
    [신약 승인 도전] HLB, 간암 신약 FDA 재신청…전체생존기간 23.8개월 입증
    1 outlets · 1 articlesFirst report Oct 18 10:05 CBC뉴스Regulatory approval

Latest HLB news Korean headlines